OPT-302 Combination Therapy Demonstrated Superiority in Visual Acuity over Lucentis® The primary outcome achieved: OPT-302 + Lucentis (ranibizumab) combination therapy demonstrated a statistically significant vision benefit compared to Lucentis in wet AMD patients at 24 weeks in a trial of 366 patients Intravitreal OPT-302 combination therapy was well tolerated with a safety profile similar to… Read More »
Presented in part at: 15th Annual Angiogenesis, Exudation, and Degeneration meeting, February 2018, Miami, Florida; 41st Annual Macula Society Meeting, February 2018, Beverly Hills, California; Association for Research in Vision and Ophthalmology Annual Meeting, April–May 2018, Honolulu, Hawaii; Royal College of Ophthalmologists Annual Congress 2018, May 2018, Liverpool, United Kingdom; 36th World Ophthalmology Congress, June… Read More »
Initial Phase 1b data for KSI-301 in Wet AMD, DME, and RVO to be presented PALO ALTO, Calif., July 24, 2019 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that data from the ongoing KSI-301 clinical study will be presented… Read More »
In Brief: Symptomatic vitreomacular adhesion is associated with reduced visual acuity, which can significantly affect quality of life. This study was a prespecified analysis of the 2-year, sham-controlled OASIS trial. Clinically meaningful (≥5-point) changes in patient-reported outcomes were assessed. Ocriplasmin resulted in clinically meaningful improvements in visual function. Purpose: To evaluate patient-reported visual function after ocriplasmin… Read More »
A Revolution in Retina – In the early 1990s when I applied for a surgical retina fellowship, the results of the two multicenter trials designed to test the efficacy of subfoveal laser photocoagulation in new and recurrent choroidal neovascularization in AMD were reported. This reaffirmed my decision to become a surgeon and confirmed my impressions… Read More »
EARN CREDIT NOW Course Director: Pravin U. Dugel, MD Release Date: March 31, 2019 Expiration Date: March 31, 2020 Credits Available: Physicians – maximum of 0.5 AMA PRA Category 1 Credits™ Jointly provided by Postgraduate Institute for Medicine and Catamount Medical Education Supported by an independent educational grant from Novartis Pharmaceuticals Corporation Release Date: March… Read More »
Oxurion NV Reports Positive Topline Phase 1 Results with THR-149, a novel, potent plasma kallikrein inhibitor for the treatment of DME Topline data show that THR-149 is well-tolerated and safe. No dose-limiting toxicities or drug-related serious adverse events reported. Rapid onset of action starting at Day 1 with increasing average improvement in Best Corrected Visual… Read More »
Purpose: The purpose of this article is to examine visual acuity (VA) outcomes and treatment patterns in neovascular age-related macular degeneration (nAMD) eyes switching between ranibizumab and aflibercept in routine clinical practice. Methods: Electronic medical records were used to identify nAMD eyes receiving ranibizumab or aflibercept with 12 months’ follow-up since switching antivascular endothelial growth… Read More »
Pravin U. Dugel, Adrian Koh, Yuichiro Ogura, Glenn Jaffe, Ursula Schmidt-Erfurth, David Brown, Andre V. Gomes, James Warburton, Andreas Weichselberger, Frank G. Holz Abstract ObjectiveTwo similarly designed, phase 3 trials (HAWK and HARRIER) compared brolucizumab, a single-chain antibody fragment that inhibits vascular endothelial growth factor-A, with aflibercept to treat neovascular age-related macular degeneration (AMD). DesignDouble-masked, multicenter, active-controlled, randomized trials. Patients(N = 1817) with untreated,… Read More »
Pravin Dugel, MD, R. Ross Lakhanpal, MD Channels: Retina | Posted 4/5/2019 Pravin Dugel, MD, joins Ross Lakhanpal, MD, to define, discuss, and forecast the future of informatics in retina. In Dr. Dugel’s view, the informatics platforms used in other fields could translate to retina and, when they arrive, will change the preparation and… Read More »
